Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome

• US 5,695,766 A
• Filed: 10/05/1993
• Issued: 12/09/1997
• Est. Priority Date: 10/30/1992
• Status: Expired due to Term

• Current Assignee: Iowa State University Research Foundation Incorporated (Iowa State University), Zoetis WHC 2 LLC (Zoetis Incorporated)
• Original Assignee: Iowa State University Research Foundation Incorporated (Iowa State University), Solvay Animal Health, Inc. (Pfizer Inc.)
• Inventors: Meng, Xiang-Jin, Lum, Melissa Anne, Halbur, Patrick G., Paul, Prem S., Lyoo, Young S.
• Primary Examiner(s): Caputa, Anthony C.
• Application Number:
  US08/131,625
• Time in Patent Office: 1,526 Days
• Field of Search: 435/235.1, 435/236, 435/237, 435/238, 435/239, 424/204.1, 424/209.1, 424/815, 424/218.1
• US Class Current: 424/204.1
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/543 intranasal
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2770/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2770/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2770/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: G01N 33/56983 Viruses
• CPC Class Codes: Y10S 424/815 Viral vaccine for porcine species, e.g. swine

Abstract

The present invention provides a vaccine which protects pigs from a virus and/or an infectious agent causing a porcine respiratory and reproductive disease, a method of protecting a pig from a disease caused by a virus and/or an infectious agent which causes a respiratory and reproductive disease, a method of producing a vaccine against a virus and/or an infectious agent causing a porcine reproductive and respiratory disease, and a biologically pure sample of a virus and/or infectious agent associated with a porcine respiratory and reproductive disease, particularly the Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), and an isolated polynucleotide which is at least 90% homologous with a polynucleotide obtained from the genome of a virus and/or infectious agent which causes a porcine respiratory and reproductive disease.

Claims

1. A naturally occurring isolated virus which causes porcine reproductive and respiratory syndrome (PRRS), wherein inoculation of five-week-old colostrum-deprived, caesarean-derived pigs with 10⁵ TCID₅₀ of said virus results in lesions in at least 51.9% of lung tissue 10 days post-infection.

2. The isolated virus of claim 1, wherein said virus has less than 90% polynucleotide sequence identity to Lelystad virus in any one of open reading frames 5 (SEQ ID NO:

12), 6 (SEQ ID NO;

15) or 7 (SEQ ID NO;

18).

6. A composition comprising the isolated virus of claim 1 and a physiologically acceptable carrier.

7. A vaccine which protects a pig against porcine reproductive and respiratory syndrome (PRRS), comprising a, inactivated or attenuated virus prepared by serial passage in cell culture and a physiologically acceptable carrier, wherein prior to inactivation or attenuation, said virus is the virus of claim 1.

8. The vaccine of claim 7, wherein lung lesions in said five-week-old colostrum-deprived, caesarean-derived pigs are reduced by a statistically significant amount wherein said amount is significant a p value less than 0.01, relative to lung lesions in uninoculated five-week-old colostrum-deprived, caesarean-derived pigs.

9. The vaccine of claim 7, comprising an effective amount of said inactivated or attenuated virus which lowers the average clinical respiratory score of a group of colostrum-deprived, caesarean-derived pigs inoculated with said vaccine, then subsequently challenged with live PRRS virus, relative to a group of identically challenged colostrum-deprived, caesarean-derived pigs not inoculated with the vaccine.

10. The vaccine of claim 7 further comprising an an adjuvant.

11. A method of protecting a pig from a porcine reproductive and respiratory disease, comprising administering an effective amount of the vaccine of claim 7 to a pig in need of protection against said disease.

12. The method of claim 11, wherein said vaccine is administered orally or parenterally.

13. The method of claim 11, wherein said vaccine is administered intramuscularly, intradermally, intravenously, intraperitoneally, subcutaneously or intranasally.

14. The method of claim 11, wherein said vaccine is administered to a sow in need of protection against said disease.

3. A naturally occurring isolated virus selected from the group consisting of ISU-12 (VR 2385 and VR 2386), ISU-22 (VR 2429), ISU-79 (VR 2474) and ISU-28.

4. The isolated virus of claim 3, selected from the group consisting of ISU-12 (VR 2385 and VR 2386), ISU-22 (VR 2429) and ISU-79 (VR 2474).

5. The isolated virus of claim 4 which is ISU-12 (VR 2385 and VR 2386).